+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy

Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy

Maturitas 48(1): 65-70

Objective: To evaluate the pharmacodynamic effects of a novel intrauterine drug delivery system, FibroPlant-levonorgestrel (LNG), on the endometrium in 24 postmenopausal women using estrogen substitution therapy (EST) to suppress climacteric symptoms. Design: A 3-year non-comparative prospective clinical trial. Subjects: The treatment with the FibroPlant-LNG intrauterine system (IUS), releasing 14 mug of LNG per day, was part of a regimen for estrogen substitution therapy in symptomatic postmenopausal women to prevent endometrial proliferation and bleeding. The majority of women received percutaneous 17beta estradiol, 1.5 mg daily, or an equivalent dose by patch or orally, on a continuous basis. Outcome measures: Menstrual pattern, endometrial histology and ultrasonographic evidence of endometrial suppression, after 3 years of use. Results: The endometrial histology specimen showed profound endometrial suppression with glandular atrophy and stroma decidualization in all women. On transvaginal ultrasound, this corresponds with a thin endometrium (<5 mm) and clinically with a "bleed-free" menstrual pattern or amenorrhoea. Conclusion: The results of this 3-year study in 24 postmenopausal women using EST suggest that the FibroPlant-LNG IUS is effective in causing strong suppression of the endometrium during the entire period of EST. Target delivery in the uterine cavity could be the preferred route of administering a progestin to oppose estrogen stimulation of the endometrium.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 012036404

Download citation: RISBibTeXText

PMID: 15223110

DOI: 10.1016/j.maturitas.2003.07.002

Related references

Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. Maturitas 57(2): 205-209, 2007

The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric 18(4): 470-482, 2016

Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women. Gynecological Endocrinology 20(6): 336-342, 2005

Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia. Nan Fang Yi Ke Da Xue Xue Bao 32(9): 1350-1354, 2013

Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecologic Oncology 95(3): 762-764, 2004

Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstetricia et Gynecologica Scandinavica 82(6): 580-582, 2003

Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception 80(1): 84-89, 2009

Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia. Journal of Research in Medical Sciences 19(8): 686-690, 2014

Protective effect of intrauterine release of levonorgestrel on pelvic infection three years' comparative experience of levonorgestrel releasing and copper releasing intrauterine devices. Obstetrics and Gynecology 77(2): 261-264, 1991

The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years). Minerva Ginecologica 54(3): 271-278, 2002

Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstetrics and Gynecology 111(2 Pt 2): 547-549, 2008

Efficacy and safety of low-dose levonorgestrel-releasing intrauterine system in Chinese women: a multicenter, single-arm, open labeled interventional trial. Zhonghua Fu Chan Ke Za Zhi 53(6): 409-413, 2018

Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 18(10): 1060-1066, 2012

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. American Journal of Obstetrics and Gynecology 172(1 PART 1): 114-119, 1995

Efficacy and safety of a low-dose levonorgestrel intrauterine system (LNG-IUS12) according to age, parity, and body mass index over 5 years of use. Fertility and Sterility 106(3): E7-E8, 2016